American Home Products Corp. and Interneuron Pharmaceuticals pulled two big-selling prescription diet drugs off the market in a worldwide action taken at the request of the U.S. Food & Drug Administration. FDA cited evidence suggesting the products are linked to serious heart damage. AHP's Redux (dexfenfluramine) approved for sale last June, had sales of more than $130 million last year and was a candidate for a major direct-to-consumer advertising push. The other drug, Pondimin (fenfluramine), had 1996 sales of more than $170 million. The success of the two prescription products had hurt OTC diet aid and weight-loss center sales. Pondimin is one half of the popular diet drug combination fen-phen.
Copyright September 1997, Crain Communications Inc.